Table 38.

Antidotal therapy.

	N (%)a
N-Acetylcysteine	751 (31.2)
Naloxone/nalmefene	331 (13.7)
Thiamine	276 (11.5)
Sodium bicarbonate	230 (9.5)
Folate	192 (8.0)
Fomepizole	85 (3.5)
Physostigmine	77 (3.2)
Glucagon	73 (3.0)
Calcium	64 (2.7)
Atropine	44 (1.8)
Flumazenil	36 (1.5)
Insulin-euglycemic therapy	35 (1.5)
Cyproheptadine	30 (1.2)
Octreotide	29 (1.2)
Lipid resuscitation therapy	27 (1.1)
Carnitine	25 (1.1)
Vitamin K	20 (0.8)
Methylene blue	19 (0.8)
Fab for digoxin	19 (0.8)
Pyridoxine	16 (0.7)
2-PAM	6 (0.2)
Hydroxocobalamin	6 (0.2)
Dantrolene	4 (0.2)
Ethanol	3 (0.1)
Bromocriptine	3 (0.1)
Nitrites	3 (0.1)
Anticoagulation reversal	1 (< 0.1)
Andexanet	1 (< 0.1)
Botulinum antitoxin	1 (< 0.1)
Factor replacement	1 (< 0.1)
Protamine	1 (< 0.1)
Silimarin	1 (< 0.1)
Total	2410 (100)

^aPercentages are based on the total number of antidotes administered (N = 2410); 1889 (26.3%) Registry cases received at least one antidote. Cases may have involved the use of multiple antidotes